Evidence map›Paper›PMID 29641536›Full record

ArticlePloS one2018

Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients.

María Iglesias-Escudero, Marco Antonio Moro-García, Raquel Marcos-Fernández, Alejandra García-Torre, Marta Elena Álvarez-Argüelles, María Luisa Suárez-Fernández, Pablo Martínez-Camblor, Minerva Rodríguez, Rebeca Alonso-Arias

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · on this map
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

María Iglesias-EscuderoImmunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Marco Antonio Moro-GarcíaImmunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.ORCID 0000-0001-9601-5757
Raquel Marcos-FernándezImmunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Alejandra García-TorreImmunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Marta Elena Álvarez-ArgüellesDepartment of Microbiology, HUCA, Oviedo, Spain.
María Luisa Suárez-FernándezNephrology Department, HUCA, Oviedo, Spain.
Pablo Martínez-CamblorStatistics Department, HUCA, Oviedo, Spain.
Minerva RodríguezNephrology Department, HUCA, Oviedo, Spain.
Rebeca Alonso-AriasImmunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CMV (cytomegalovirus) antibody titers are related to immune alterations and increased risk of mortality. To test whether they represent a marker of infection history, we analyzed the effect of viral reactivations on the production of specific antibodies in kidney transplant patients. We quantified CMV-DNAemia and antibody titers in 58 kidney transplant patients before transplantation and during a follow-up of 315 days (standard deviation, SD: 134.5 days). In order to calculate the intensity of the infection, we plotted the follow-up time of the infection on the x-axis and the number of DNA-CMV copies on the y-axis and calculated the area under the curve (CMV-AUC). The degree of T-lymphocyte differentiation was analyzed with flow cytometry, the cells were labelled with different monoclonal antibodies in order to distinguish their differentiation state, from naive T-cells to senescent T-cells. Peak viremia was significantly higher in patients experiencing a primary infection (VI) compared to patients experiencing viral reactivation (VR). Our data indicate that the overall CMV viral load over the course of a primary infection is significantly higher than in a reactivation of a previously established infection. Whereas patients who experienced an episode of CMV reactivation during the course of our observation showed increased levels of CMV-specific antibodies, patients who did not experience CMV reactivation (WVR) showed a drop in CMV antibody levels that corresponds to an overall drop in antibody levels, probably due to the continuing immunosuppression after the renal transplant. We found a positive correlation between the CMV viremia over the course of the infection or reactivation and the CMV-specific antibody titers in the examined patients. We also observed a positive correlation between anti-CMV titers and T-cell differentiation. In conclusion, our data show that anti-CMV antibody titers are related to the course of CMV infection in kidney transplant patients.

Indexed as

Virus ActivationAdultAgedAntibodies, ViralArea Under CurveCD8-Positive T-LymphocytesCytomegalovirusCytomegalovirus InfectionsDNA, ViralFemaleFollow-Up StudiesHLA AntigensHumansImmunophenotypingImmunosuppression TherapyKidney Failure, ChronicAntibodies, ViralDNA, ViralHLA Antigens

Identifiers

PMID29641536
PMCPMC5895001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.